The 5-substituted piperazine as a novel secondary pharmacophore greatly improving the physical properties of urea-based inhibitors of soluble epoxide hydrolase

Bioorganic and Medicinal Chemistry

Volumn 14, Issue 19, 2006, Pages 6586-6592

  Li, Hui Yuan ^a   Jin, Yi ^a   Morisseau, Christophe ^b   Hammock, Bruce D ^b   Long, Ya Qiu ^a  

^a SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

1 adamantanyl urea based inhibitors; Chiral pool synthesis; Hypertension; Piperazine; Secondary pharmacophore; Soluble epoxide hydrolase; Vascular inflammation; Water solubility

Indexed keywords

1 ADAMANTAN 1 YL 3 [2 (5 BENZYLPIPERAZIN 2 YL)ETHYL]UREA; 1 ADAMANTAN 1 YL 3 [2 (5 ISOPROPYLPIPERAZIN 2 YL)ETHYL]UREA; 1 ADAMANTAN 1 YL 3 [2 (OCTAHYDROPYRROLO[1,2 A]PIPERAZIN 3 YL)ETHYL]UREA; 1 ADAMANTAN 1 YL 3 [2 [5 (3 HYDROXYPROPYL)PIPERAZIN 2 YL]ETHYL]UREA; EPOXIDE HYDROLASE; HYDROLASE INHIBITOR; PIPERAZINE DERIVATIVE; UNCLASSIFIED DRUG; UREA DERIVATIVE;

ARTICLE; DRUG DESIGN; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; HYPERTENSION; IC 50; INFLAMMATION; MELTING POINT; PHARMACOPHORE; SOLUBILITY; STRUCTURE ACTIVITY RELATION; SUBSTITUTION REACTION;

CHEMISTRY, PHYSICAL; ENZYME INHIBITORS; EPOXIDE HYDROLASES; HUMANS; INDICATORS AND REAGENTS; MAGNETIC RESONANCE SPECTROSCOPY; PIPERAZINES; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; STRUCTURE-ACTIVITY RELATIONSHIP; UREA;

MAMMALIA;

EID: 33747157258     PISSN: 09680896     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmc.2006.06.005     Document Type: Article

References (29)

1. Newman J.W., Morisseau C., and Hammock B.D. Prog. Lipid Res. 44 (2005) 1-51
2. Fretland A.J., and Omiecinski C.J. Chem. Biol. Interact. 129 (2000) 41-59
3. Capdevila J.H., Falck J.R., and Harris R.C. J. Lipid Res. 41 (2000) 163-181
4. Oltman C.L., Weintraub N.L., VanRollins M., and Dellsperger K.C. Circ. Res. 83 (1998) 932-939
5. Fisslthaler B., Popp R., Kiss L., Potente M., Harder D.R., Fleming I., and Busse R. Nature 401 (1999) 493-497
6. Moghaddam M.F., Grant D.F., Cheek J.M., Greene J.F., Williamson K.C., and Hammock B.D. Nat. Med. 3 (1997) 562-567
7. Morisseau C., Goodrow M.H., Dowdy D., Zheng J., Greene J.F., Sanborn J.R., and Hammock B.D. Proc. Natl. Acad. Sci. U.S.A. 96 (1999) 8849-8854
8. Morisseau C., and Hammock B.D. Annu. Rev. Pharmacol. Toxicol. 45 (2005) 311
9. Schmelzer K.R., Kubala L., Newman J.W., Kim I.H., Eiserich J.P., and Hammock B.D. Proc. Natl. Acad. Sci. U.S.A. 102 (2005) 9772-9777
10. Liu Y., Zhang Y.J., Schmelzer K., Lee T.S., Fang X., Zhu Y., Spector A.A., Gill S., Morisseau C., Hammock B.D., and Shyy J.Y.J. Proc. Natl. Acad. Sci. U.S.A. 102 (2005) 16705-16747
11. Argiriadi M.A., Morisseau C., Hammock B.D., and Christianson D.W. Proc. Natl. Acad. Sci. U.S.A. 96 (1999) 10637-10642
12. Argiriadi M.A., Morisseau C., Goodrow M.H., Dowdy D.L., Hammock B.D., and Christianson D.W. J. Biol. Chem. 275 (2000) 15265-15270
13. Imig J.D., Zhao X., Capdevila J.H., Morisseau C., and Hammock B.D. Hypertension 39 (2002) 690-694
14. Newman J.W., Denton D.L., Morisseau C., Koger C.S., Wheelock C.E., Hinton D.E., and Hammock B.D. Environ. Health Perspect. 109 (2001) 61-66
15. Yu Z., Xu F., Huse L.M., Morisseau C., Draper A.J., Newman J.W., Parker C., Graham L., Engler M.M., Hammock B.D., Zeldin D.C., and Kroetz D.L. Circ. Res. 87 (2000) 992-998
16. Morisseau C., Goodrow M.H., Newman J.W., Wheelock C.E., Dowdy D.L., and Hammock B.D. Biochem. Pharmacol. 63 (2002) 1599-1608
17. Kim I.H., Morisseau C., Watanabe T., and Hammock B.D. J. Med. Chem. 47 (2004) 2110-2122
18. Kim I.H., Heirtzler F.R., Morisseau C., Nishi K., Tsai H.-J., and Hammock B.D. J. Med. Chem. 48 (2005) 3621-3629
19. Todorovic A., and Haskell-Luevano C. Peptides 26 (2005) 2026-2036
20. Donnelly L.E., and Rogers D.F. Curr. Opin. Drug Discov. Dev. 6 (2003) 815-826
21. Brown H., and Heim P. J. Org. Chem. 38 (1973) 912-916
22. Jones P.D., Wolf N.M., Morisseau C., Whetstone P., Hock B., and Hammock B.D. Anal. Biochem. 343 (2005) 66-75
23. The water solubility (S, mg/mL) was determined experimentally at 25 ± 1.0 °C. For compound 1a with a UV chromophore, an excess of the test compound was added to a vial containing sodium phosphate buffer, 0.1 M, pH 7.4 (200 μL), and a suspension of the mixture was equilibrated during 1 h of sonication and 1 h of shaking, followed by centrifugation (5 min, 8000 rpm). The water supernatant was scanned on UV spectrophotometer (HITACHI U-2010) to get its UV absorbance at the wavelength of 254 nm. A regression curve for compound 1a was obtained from six standard stock solutions (r = 0.99) by using UV spectrometry at the same wavelength. Then, the absolute amount of compound 1a was calculated. For compounds 1b-c without a UV chromophore, to an exactly weighed amount of test compound was added PBS by an increment of 5 μL with pipet until the solid was completely dissolved accompanied with frequent shaking at 25 ± 1.0 °C.
24. Banerjee S., Yalkowsky S.H., and Valvani S.C. Environ. Sci. Technol. 14 (1980) 1227-1229
25. Dietze E.C., Kuwano E., and Hammock B.D. Anal. Biochem. 216 (1994) 176-187
26. Broadbent W., Morley J.S., and Stone B.E. J. Chem. Soc. C 15 (1979) 2632-2636
27. Castro B., Dormoy J.R., Evin G., and Selve C. Tetrahedron Lett. 14 (1975) 1219-1221
28. Abiko T., and Sekino H. Chem. Pharm. Bull. 37 (1989) 391-396
29. Pickenhagen W., Dietrich P., Keil B., Polinsky J., Nouaille F., and Lederer E. Helv. Chim. Acta 58 (1975) 1078-1084